Integrating Blood-Based Biomarkers for Alzheimer’s Risk Assessment
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Integrating Blood-Based Biomarkers for Alzheimer’s Risk Assessment
-
ナレーター：
-
著者：
このコンテンツについて
In this episode of Results are In by Quest Diagnostics, Amanda Benson is joined by Dr. Michael Racke, Medical Director for Neurology at Quest Diagnostics, to discuss the groundbreaking role blood-based biomarkers play in assessing Alzheimer’s disease risk. Dr. Racke shares his expert insights on how these biomarkers are revolutionizing early risk detection and diagnosis, offering primary care physicians a proactive tool to identify Alzheimer’s before cognitive symptoms appear. From the evolution of Alzheimer's diagnostics to the practical application of plasma-based tests, Dr. Racke explains how integrating these tests into routine health visits can enable earlier interventions and better patient outcomes. He also discusses how blood-based biomarkers, in conjunction with digital cognitive assessments, are improving the sensitivity of Alzheimer’s screenings. This episode is a must-listen for anyone interested in the future of Alzheimer’s diagnostics and the power of early detection in cognitive health.
Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics
LinkedIn @QuestDiagnostics
Presented by Quest Diagnostics
www.questdiagnostics.com